GlassScriptPhysician profile
Kurt K Thomas
NPI 1225002801
$1,591.29
in general payments reported to CMS, 2019-2025
24 companies · $80.06 in 2025
The $80.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $950 · 2020: $64.11 · 2021: $123 · 2022: $110 · 2023: $20.69 · 2024: $244 · 2025: $80.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $282.85 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $220.76 | 2019 | |
| Ceribell, INC. | $166.87 | 2024 | Pocket Eeg Device |
| Pfizer INC. | $153.27 | 2019-2023 | |
| Amarin Pharma, INC. | $130.53 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $122.60 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.53 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $67.91 | 2019-2025 | Trintellix |
| Amgen INC. | $39.49 | 2019 | |
| Lilly USA, LLC | $39.14 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $33.46 | 2019 | |
| Glaxosmithkline, LLC. | $28.25 | 2019 | |
| Daiichi Sankyo INC. | $25.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.20 | 2019 | |
| Allergan, INC. | $23.47 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $18.68 | 2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $15.61 | 2020 | |
| Jazz Pharmaceuticals INC. | $15.03 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.69 | 2020 | |
| Merck Sharp & Dohme LLC | $12.94 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.48 | 2019 | |
| Abbvie INC. | $11.95 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.